Megan Shaffer, PhD, S(ACHI)

Dr. Megan Shaffer completed her PhD in microbiology and immunology at Louisiana State University Health Sciences Center, Shreveport, and continued post-doctoral training at Louisiana State University Health Sciences Center, New Orleans. Dr. Shaffer holds a certificate of qualification from the New York State Department of Health to act as a laboratory director in the categories of histocompatibility, transplant monitoring, forensic identity and parentage/identity testing. She is board certified as an associate of the American College of Histocompatibility and Immunogenetics (ACHI).

Ruth P Koester, PhD, F(ACHI)

Dr. Ruth Koester is a fellow of the American College of Histocompatibility and Immunogenetics (ACHI), and she is a member of American Society for Histocompatibility and Immunogenetics (ASHI), the European Federation for Immunogenetics (EFI) and the World Marrow Donor Association (WMDA). She earned a BS from Cornell University and a PhD in Genetics from North Carolina State University.

<span>Why a biometric screening is essential</span>
August 30, 2023

Why a biometric screening is essential

What is a biometric screening?The Centers for Disease Control and Prevention (CDC) defines biometric screening as “themeasurement of physical characteristics such as height, weight, body mass index (BMI), bloodpressure, blood cholesterol and blood glucose that can be taken at the work site and used as part of a workplace health assessment.” This information becomes the baseline to monitor and evaluate changes in an employee’s health each year. 

Kathleen Bailey, MS, NP, PhD

As a Nurse Practitioner, Kathleen provided direct patient care for 5 years and also participated in clinical research and as a Director of medical staff in HIV and infectious disease private practice settings. 

<span>How Fraser found his wings at Labcorp</span>
August 25, 2023

How Fraser found his wings at Labcorp

As a kid, Fraser loved going to air shows with his father. This paved a direct line for his career aspirations, and he attended flight school at Elon Aviation in Burlington, North Carolina. While he never thought his career would take off in a way that landed him at Labcorp, he is glad it did.
August 14, 2023

Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies

This study looks into the genetic landscape of 24,639 clinical myeloid samples assessed by the IntelliGEN® Myeloid Panel showing the utility of comprehensive genomic testing to guide clinical decisions. In recent years guidelines for myeloid diseases including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN) have been updated to incorporate genomic mutation status in an increasing number of genes. We observed an average of 1.95 mutations per patient with 48.7% having mutations in genes used in diagnostic criteria while 61.6% of MDS patients had prognostic mutations. In total, we detected over 48,000 variants across the panel of 50 genes, shedding light on the intricate genetic tapestry of myeloid disease observed in real-world samples. This expansive retrospective study underscores the power of NGS testing in guiding clinical decisions within routine care and illuminates the mutational landscape within the myeloid patient community.